A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Clinical trial NCT05303467 · RECRUITING

Trial details

NCT number: NCT05303467
Sponsor: Boston Scientific Corporation
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Glioblastoma Multiforme Recurrent Glioblastoma

Start date: 2022-07-30
Primary completion: 2026-10-31
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.